

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:

RTSP-0211

Inventors:

Bennett et al.

Serial No.:

10/018,445

Filing Date:

December 13, 2001

Examiner:

Not Yet Assigned

Group Art Unit:

Not Yet Assigned

Title:

Antisense Modulation of Integrin Beta 3

Expression

"Express Mail" Label No. EV104364905US Date of Deposit April 24, 2002

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the U.S. Patent and Trademark Office, Box 2327, Arlington, VA 22202

By <u>(โดยโดยวิชาติ)</u> Typed Name: Jane Massey Licata, Reg. No. 32,257

U.S. Patent and Trademark Office Box 2327 Arlington, VA 22202

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in \$1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- () In accordance with \$1.97(c), this Information Disclosure Statement is being filed after the period set forth in \$1.97(b) above but before the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311, therefore:
 - () Certification in Accordance with §1.97(e) is set forth below; or
 - () The fee of \$180.00 as set forth in \$1.17(p) is attached.
- () In accordance with \$1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with \$1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in \$1.17(i)(1).
- () Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.
- (XX) In accordance with \$1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified)

are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. <u>09/344,520</u>, filed <u>June 25, 1999</u>, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages 00.

(XX) All listed references are in the English language.

Respectfully submitted,

Jane Massylveste)

Jane Massey Licata Registration No. 32,257

Date: April 24, 2002

Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053

(856) 810-1515

Form PTO-1449 Modified	Docket No. Serial No. 10/018,445							
List of Patents and Publication Cited by Application (Use several sheets if necessa	Bennett et al.							
U.S. Department of Commerce Pate and Trademark Office	Filing Date Group							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
Hum. Cell, 19 9	Integrins in cell adhesion and signaling, 1996, 9:181-186							
AB Cheresh, Stru	Cheresh, Structure, function and biological properties of integrin alpha v beta 3 on human melanoma cells, Cancer Metastasis Rev., 1991, 10:3-10							
AC Clemetson et a	Clemetson et al., Integrins and cardiovascular disease, Cell. Mol. Life Sci., 1998, 54:502-513							
AD Elangbam et a. Pathol., 1997	Elangbam et al., Cell adhesion moleculesupdate, Vet. Pathol., 1997 , 34:61-73							
receptor", In	Horton, The alpha v beta 3 integrin "vitronectin receptor", Int. J. Biochem. Cell. Biol., 1997, 29:721-725							
Glanzmann's t. alpha IIb bet	Kato, The biologic and clinical spectrum of Glanzmann's thrombasthenia: implications of integrin alpha IIb beta 3 for its pathogenesis, Crit. Rev. Oncol. Hematol., 1997, 26:1-23							
AG LaFlamme et a connectors to	LaFlamme et al., Integrin cytoplasmic domains as connectors to the cell's signal transduction apparatus, Matrix Biol., 1997, 16:153-163							
AH Rodan et al.,	Rodan et al., Integrin function in osteoclasts, J. Endocrinol., 1997 , 154 Suppl:S47-56							
AI Ruoslahti, I targets for t 1417	Ruoslahti, Integrins as signaling molecules and targets for tumor therapy, Kidney Int., 1997 , 51:1413-1417							
signaling by Haemost., 199	Shattil, Regulation of platelet anchorage and signaling by integrin alpha IIb beta 3, Thromb. Haemost., 1993, 70:224-228							
AK Trikha et al.	Trikha et al., Human prostate carcinoma cells express functional alphaIIb(beta)3 integrin, Cancer Res., 1996,							
EXAMINER	DATE CONSIDERED							

Form PTC	O-1449 Modified	Docket No. RTSP-0211	Serial No. 10/018,445						
List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Applicant Bennett et al.							
		Filing Date December 3, 2001	Group Not Yet Assigned						
OTHER DOCUMEN	TS (Including Author,	Title, Date, Perti	nent Pages, Etc.)						
AL	Akhtar et al., "Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes)", Nucleic Acids Research 1991 19(20):5551-5559								
AM	Dallabrida et al., "Angiogenesis inhibition in vitro by integrin beta 3 antisense expression", FASEB J. 1998 12(5):A1346								
AN	Dallabrida et al., "Inhibition of angiogenesis in vitro by integrin beta 3 antisense expression", Blood 1997 90(10:286a								
AO	Sanghvi Y.S., "Heterocyclic base modifications in nucleic acids and their applications in antisense oligonucleotides", Antisense Research and Application 1999 273-288								
EXAMINER		DATE CONSIDERED							

Form PTO-1449 Modified			Docket No.		Serial No.						
			RTSP-	0211	10/018,445						
List of Patents and Publications			Applicant								
Cited by Application				Bennett et al.							
(Use several sheets if necessary)			-								
U.S. Depart				Filing Date Group				_			
Patent and Trademark Office			ce	December 13, 2001 Not Yet Assigned							
U.S. PATENT DOCUMENTS											
Examiner's		Document	Date	Na	Name		Class	Subclass			
Initial		No.									
	AA	5,578,704	11/26/19	96 Kir	Kim et al.		530	388.22			
	AB	5,652,109	07/29/19	97 Kir	Kim et al.		435	7.1			
	AC	5,652,110	07/29/19	97 Kir	Kim et al.		435	7.1			
	AD	5,789,573	08/04/199	8 Ba.	Baker et al.		536	24.5			
	AE										
	AF										
	AG										
	AH						<u> </u>				
	AI										
	AJ					,	ļ				
	AK										
	AL										
	AM										
	AN						<u> </u>				
FOREIGN PATENT DOCUMENTS											
Examiner's Initial		Document No.	Date		Country	Country		Translation YES NO			
	AO										
-	AP										
	AQ										
	AR							_			
	AS							 			
	AT										
- : ::	AU										
	AV							-			
	AW	_									
	AX		L	ī				1			
EXAMINER DAT					DATE CONSIDERED						